Evidence map›Paper›PMID 40171736›Full record

ArticleNanomedicine (London, England)2025

Terbinafine for prostate cancer: development of coated zein nanospheres for ameliorated pro-apoptosis in PC3 cells.

Majid M Al-Sawahli, Yasmin A El-Feky, Ahmed J Mohammed, Nada M Mohamed, Rania El-Telbany, Zaenah Zuhair Alamri, Sahar Jameel Melebary, Mohammad Y Alfaifi, Serag Eldin I Elbehairi, Ayman M Noreddin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Majid M Al-SawahliDepartment of Pharmaceutics, College of Pharmacy, The Islamic University, Najaf, Iraq.ORCID 0000-0001-5521-4901
Yasmin A El-FekyDepartment of Pharmaceutics, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo, Egypt.
Ahmed J MohammedDepartment of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Najaf, Iraq.
Nada M MohamedPharmaceutical Chemistry Department, Modern University for Technology and Information (MTI), Cairo, Egypt.
Rania El-TelbanyDepartment of Biochemistry, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo, Egypt.
Zaenah Zuhair AlamriDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Sahar Jameel MelebaryDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Mohammad Y AlfaifiBiology Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia.ORCID 0000-0003-4310-3539
Serag Eldin I ElbehairiBiology Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia.
Ayman M NoreddinDepartment of Internal Medicine, School of Medicine, University of California, Irvine, CA, USA.
Ashraf B Abdel-NaimDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Ebtesam M AlolayanDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Dalia F El-TelbanyDepartment of Pharmaceutics, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo, Egypt.ORCID 0000-0001-9705-6497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe purpose of this study was to investigate comparatively the anticancer potential of Terbinafine loaded Dextran Sulphate coated Zein nanospheres against human prostate cancer PC3 cells to enhance the repurposing profile of terbinafine utilizing optimized nano-sized delivery systems. MATERIALS &

methodsThe formula was fabricated using the thin film hydration technique. Particle size analysis, drug diffusion, and encapsulation efficiency were considered when evaluating the fabricated formula, which were developed using a Box-Behnken statistical design.

resultsDue to the formula optimization, the mean particle size was 273.2 ± 1.98 nm, the zeta potential was -38.4 ± 2.77 mV, and the amount released after 36 h was 97.4 ± 5.7%. The formula exhibited significantly reduced IC

conclusionThe optimized formula revealed enhanced pro-apoptosis in PC3 cells which support the repurposing profile of terbinafine toward prostate cancer.

Indexed as

Antineoplastic AgentsApoptosisNanospheresProstatic NeoplasmsTerbinafineZeinCell CycleCell ProliferationDrug CarriersHumansMaleParticle SizePC-3 CellsAntineoplastic AgentsDrug CarriersTerbinafineZeinapoptosisnanoparticlesPC3Prostate cancerterbinafinezein

Identifiers

PMID40171736
PMCPMC11988259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.